Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism

Human Psychopharmacology

Volumn 24, Issue 2, 2009, Pages 129-133

  Kim, Jong Hoon ^a   Byun, Hee Jung ^b,c  

^a Gachon University College of Medicine   (South Korea)

^b Seoul Children's Hospital   (South Korea)

^c Yongin Mental Hospital   (South Korea)

Author keywords

Antipsychotics; Cognitive dysfunction; Drug induced parkinsonism; Perceptual dysfunction; Schizophrenia

Indexed keywords

BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; EMONAPRIDE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SULPIRIDE; ZOTEPINE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CLINICAL ASSESSMENT TOOL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; COPING BEHAVIOR; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FRANKURT COMPLAINT QUESTIONNAIRE; HUMAN; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RESTLESSNESS; SCHIZOPHRENIA; SELECTIVE ATTENTION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HOSPITALIZATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSONIAN DISORDERS; PERCEPTUAL DISORDERS; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 63849175960     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1009     Document Type: Article

References (36)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th edn., American Psychiatric Press: Washington DC.
2. Ballenger JC. 2000. Benzodiazepine receptor agonists and antagonists. In Comprehensive textbook of psychiatry, 7th edn, Sadock BJ, Sadock VA (eds). Lippincott Williams & Willdns: Philadelphia; 2317-2324.
3. BarnesTR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Chang HI, Kim JK, Yum TH, et al. 1995. Manual of Kyung Hee Frankfurt Beschwerde Fragebogen. J Korean Neuropsychiatr Assoc 34: 754-771.
5. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. 2007. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 22: 1901-1911.
6. Cuesta MJ, Peralta V, Juan JA. 1996. Abnormal subjective experiences in schizophrenia: its relationships with neuropsychological disturbances and frontal signs. Eur Arch Psychiatry Clin Neurosci 246: 101-105.
7. Gerlach J, Larsen EB. 1999. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl 395: 113-117.
8. Gold JM, Egan MF, Kirch DG, et al. 1991. Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings. Biol Psychiatry 30: 587-599.
9. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Pubi No ADM 76-338) U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD
10. Haddad PM, Dursun SM. 2008. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 23(Suppl 1): 15-26.
11. Hansen L, Kingdom D. 2006. Akathisia as a risk factor for suicide. Br J Psychiatry 188: 192.
12. Hofer A, Rettenbacher MA, Widschwendter CG, et al. 2006. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci 256: 246-255.
13. Karson CN, Lyon N, Amick R, Bracha HS, Guggenheim FG. 1993. The profile of cognitive impairment in elderly dyskinetic subjects. J Neuropsychiatry Clin Neurosci 5: 61-65.
14. Kim JH, Jung HY, Kang UG, et al. 2002. Metric characteristics of the DIEPSS: a practical combined rating scale for drug-induced movement disorders. Mov Disord 17: 1354-1359.
15. Kim JH, Jin YH, Kang UG, et al. 2005. Neuroleptic-induced acute and chronic akathisia: a clinical comparison. Mov Disord 20: 1667-1670.
16. Krausz M, Moritz SH, Naber D, Lambert M, Andresen B. 1999, Neuroleptic- induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia. Eur Psychiatry 14: 84-88.
17. Krawiecka M, Goldberg D, Vaughan M. 1977. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica 55: 299-308.
18. Loas G, Yon V Brien D. 2002. Dimensional structure of the Frankfurt Complaint Questionnaire. Compr Psychiatry 43: 397-403.
19. Marsh L. 2000. Neuropsychiatric aspects of Parkinson's disease. Psychosomatics 41: 15-23.
20. Meyer JM, Simpson GM. 2000. Anticholinergics and amatadine. In Comprehensive Textbook of Psychiatry, 7th edn, Sadock BJ, Sadock VA (eds). Lippincott Williams & Wilkins: Philadelphia; 2276-2282.
21. Naber D, Karow A. 2001. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 11(Suppl 4): 391-396.
22. Owens DGC. 1999. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge UniversityPress: Cambridge.
23. Palmer BW, Heaton RK, Jeste DV. 1999. Extrapyramidal symptoms and neuropsychological deficits in schizophrenia. Biol Psychiatry 45: 791-794.
24. Poewe W. 2006. The natural history of Parkinson's disease. J Neurol 253(Suppl 7): V112-VII6.
25. Prouteau A, Verdoux H, Briand C, et al. 2004. Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophr Res 69: 85-91.
26. Rey MJ, Schulz P, Costa C, Dick P, Tissot R. 1989. Guidelines for the dosage of neuroleptics. I; chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 4: 95-104.
27. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
28. Süllwold L. 1977. Symptome schizophrener Erkrankungen: Uncharakteristische Basisstörungen. Springer: Berlin.
29. Tarsy D. 1983. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 6(Suppl 1): S9-L S26.
30. Tarsy D, Baldessaxini RJ, Thrazi Fl. 2002. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16: 23-45.
31. Van Putten T, Marder SR. 1987. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 48(Suppl): 13-19.
32. Van Putten T, May PR, Marder SR, Wittinann LA. 1981. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187-190.
33. Van Putten T, May PR, Marder SR. 1984. Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 141: 16-19.
34. Van Putten T, May PR. 1978. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 35: 477-480.
35. Voruganti LN, Awad AG. 2002. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 56: 37-46.
36. Voruganti L, Awad AG. 2004. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171: 121-132.